Bivozon Clopidogrel Tablet 75mg (Clopidogrel Hydrogen Sulfate)

Adult dosage

○ Adults 1. Patients with ischemic stroke, myocardial infarction, or peripheral arterial disease: Administer clopidogrel 75 mg orally once daily. 2. Patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): On the day treatment with this drug is initiated, start with a loading dose of 300 mg once daily, followed by an oral maintenance dose of 75 mg once daily. Aspirin 75 ～ 325 mg must be administered concomitantly with this drug once daily. 3. Patients with atrial fibrillation: Administer 75 mg of this drug orally once daily. Aspirin 75 ～ 100 mg must be administered concomitantly with this drug once daily. ○ Patients with renal impairment: Treatment experience in patients with renal impairment is limited. ○ Patients with hepatic impairment: Treatment experience in patients with moderate hepatic disease and a bleeding diathesis is limited. This drug may be administered without regard to food.

This medication prevents blood coagulation to avert thrombus formation. However, individuals with genetically diminished function of a specific enzyme (CYP2C19) may experience reduced effectiveness of this medication, and in such cases, alternative treatment methods or medications should be considered. Additionally, taking this medication with drugs that activate the enzyme may increase the risk of bleeding, so it is advisable not to combine them. Patients with an allergy to this medication, those with severe bleeding, those with severe liver damage, nursing women, and individuals with certain genetic conditions should not take this medication. Patients at high risk for bleeding or those scheduled for surgery should exercise caution when taking this medication and must refrain from it for a certain period before surgery. Patients should remain vigilant for bleeding symptoms while on this medication, and if bleeding is suspected, they should consult a physician immediately. Caution should be taken when administering this medication alongside other antiplatelet agents, anticoagulants, non-steroidal anti-inflammatory drugs, selective serotonin reuptake inhibitors, and other drugs that increase bleeding risk. Pregnant or nursing individuals should consult with a physician, considering the potential effects on the fetus or newborn. This medication has not been established as safe and effective for children; thus, its use should be avoided in pediatric patients. Elderly patients or those with impaired kidney or liver function may have an increased risk of bleeding and may require dosage adjustments and careful monitoring. An overdose may increase the risk of bleeding, and no specific antidote exists, so treatment such as platelet transfusion may be necessary in emergencies. This medication should be stored out of the reach of children, and it is advisable not to transfer it to another container.

• Hemorrhage
• gastrointestinal hemorrhage
• hemorrhage requiring hospitalization
• purpura
• contusion
• hematoma
• epistaxis
• hematoma
• hematuria
• intraocular hemorrhage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture, and it is best stored at room temperature between 1°C and 30°C. Proper storage will help maintain the medication's effectiveness for a longer time.

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle